Shire plc
From Wikipedia, the free encyclopedia
| Shire plc (formerly: Shire Pharmaceuticals Group Plc) | |
|---|---|
 |
|
| Type | Public (LSE: SHP) |
| Founded | 1986 |
| Headquarters | Basingstoke, England, UK |
| Key people | James Cavanaugh, Chairman Matthew Emmens, CEO |
| Industry | Pharmaceuticals |
| Revenue | $2,436 million (2007) |
| Operating income | $(1,379) million (2007) |
| Net income | $(1,451) million (2007) |
| Website | www.shire.com |
Shire plc (LSE: SHP) is a British manufacturer of pharmaceuticals including Adderall XR, Carbatrol, Fosrenol, and the recently released Vyvanse. Shire was founded in the year 1986.
Contents |
[edit] Corporate strategy
Shire’s strategic goal is to become the leading specialty biopharmaceutical company, focusing on meeting the needs of specialist physicians. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. To this end, Shire primarily orients its drug research and development on the relatively common mental abnormality Attention Deficit Hyperactivity Disorder (ADHD), as is made evident by the fact that three of its currently leading medications (Adderall/Adderall XR, Daytrana, and the newly developed Vyvanse), are indicated for said disorder. However, the company also puts interest in gastrointestinal (GI) treatments, renal diseases, and human genetic therapies (HGT). This structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.
Shire’s focused strategy is to develop and market products within advanced biotechnology for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
Shire announced the acquisition of New River Pharmaceuticals on 20th February 2007.
[edit] Corporate leadership
Matthew Emmens is the Chief Executive Officer and Chairman of the Executive Committee. The non-executive Board Chairman is Dr. James Cavanaugh. The President of the Human Genetic Therapies division is Sylvie Gregoire and Mike Cola is the President of Specialty Pharmaceuticals.
[edit] Key marketed products by business unit (with indications)
[edit] ADHD
- Adderall XR: All age Attention Deficit Hyperactivity Disorder
- Daytrana: Pediatric Attention Deficit Hyperactivity Disorder
- Vyvanse: Pediatric Attention Deficit Hyperactivity Disorder
[edit] Gastrointestinal
[edit] Human Genetic Therapies
- Elaprase: Hunter Syndrome
- Replagal: Fabry's disease
[edit] Renal
- Fosrenol: Hyperphosphatemia associated with End-Stage Renal Disease
- Dynepo: Anemia associated with End-Stage Renal Disease
[edit] Other
- Carbatrol: Epilepsy
- Equetro: Bipolar I Mood Disorder
- Reminyl (also sold as Razadyne): Alzheimer's Disease
- Xagrid (sold as Agrylin in the U.S.): Essential Thrombocytosis
[edit] Financial information
Shire is traded on three stock exchanges:
- The London Stock Exchange, where its symbol is SHP.L. Shire is a constituent of the FTSE 100 Index.
- The NASDAQ, where its symbol is SHPGY.
- The Toronto Stock Exchange, where its symbol is SHQ.TO.
Shire's financial reports can be found at http://www.shire.com/shire/InvestorRelations/reports.jsp?tn=2&m1=22.
[edit] Locations
The corporate offices are located in Basingstoke, Hampshire, UK. Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. In addition, Shire owns a manufacturing site in Owings Mills, Maryland. The company has recently announced that it will move its tax domicile to Ireland. The move will be effected through the creation of a new holding company in Jersey, which will pay reduced tax on global earnings in Ireland. The new structure is thought to be motivated mainly by the rule that royalties on patents lodged in Ireland are tax free.
